Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene
Sponsor: Daiichi Sankyo Co., Ltd.
A PHASE1 clinical study on Advanced Solid Malignant Tumors, this trial is completed. The trial is conducted by Daiichi Sankyo Co., Ltd. and has accumulated 17 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Mar 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 12 earlier versions
-
Feb 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
May 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .